MedPath

Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer

Phase 2
Active, not recruiting
Conditions
Prostate Cancer
Interventions
Radiation: HDR brachytherapy monotherapy
Registration Number
NCT02077335
Lead Sponsor
CSSS de Gatineau
Brief Summary

The purpose of this study is to determine the clinical efficacy and toxicity of High-dose rate (HDR) brachytherapy as monotherapy for the treatment of low risk and intermediate risk prostate cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Male
Target Recruitment
50
Inclusion Criteria
  • Biopsy proven Adenocarcinoma of the Prostate
  • Clinical stage T1c, T2a or T2b
  • PSA less than 20 ng/ml
  • Gleason Score 6 or 7
Exclusion Criteria
  • Age less than 18 years
  • Clinical stage T2c, T3 ou T4
  • Clinical Stage N1
  • Clinical Stage M1
  • Prostate Specific Antigen (PSA) more than 20 ng/ml
  • Gleason score 8 or higher
  • IPSS score 19 or higher with alpha-blockers
  • Past radiation therapy to the pelvis
  • History of Collagen Vascular Disease
  • History of Inflammatory Bowel Disease
  • Bilateral Hip Prosthesis

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
HDR brachytherapy monotherapyHDR brachytherapy monotherapyRadiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.
Primary Outcome Measures
NameTimeMethod
Disease-free survival5 years

Disease free survival as evaluated by absence of biochemical recurrence (Phoenix criteria) and absence of clinically/radiologically diagnosed local, regional or distant recurrence.

Secondary Outcome Measures
NameTimeMethod
Genito-urinary (GU) toxicity6 weeks, 2 years and 5 years post treatment

Toxicity according to International prostate symptom score (IPSS) and Expanded Prostate Index Composite (EPIC) questionnaires.

Trial Locations

Locations (1)

CSSS de Gatineau

🇨🇦

Gatineau, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath